

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 April 2020 (16.04.2020)



(10) International Publication Number
WO 2020/073088 A1

(51) International Patent Classification:

A61K 35/747 (2015.01) *A61P 19/02* (2006.01)
A61P 29/00 (2006.01) *A61P 1/02* (2006.01)
A61P 31/04 (2006.01) *A61P 1/04* (2006.01)
A61P 31/10 (2006.01) *A61P 1/12* (2006.01)
A61P 17/02 (2006.01) *A61P 13/02* (2006.01)
A61P 17/06 (2006.01) *A61P 37/00* (2006.01)
A61P 17/10 (2006.01)

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2(a)(viii))

(21) International Application Number:

PCT/AU2019/051092

(22) International Filing Date:

10 October 2019 (10.10.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2018903822	10 October 2018 (10.10.2018)	AU
2018903823	10 October 2018 (10.10.2018)	AU
2019901175	05 April 2019 (05.04.2019)	AU
2019901176	05 April 2019 (05.04.2019)	AU

(71) Applicant: **SERVATUS LTD** [AU/AU]; Innovation Centre, University of Sunshine Coast, 90 Sippy Downs Drive, Sippy Downs, Queensland 4556 (AU).

(72) Inventor: **FINLAYSON, Wayne**; 1 Brushbox Way, Peregrine Springs, Queensland 4573 (AU).

(74) Agent: **DAVIES COLLISON CAVE PTY LTD**; 255 Elizabeth Street, Sydney, New South Wales 2000 (AU).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: METHODS OF TREATMENT OF INFLAMMATORY CONDITIONS AND ASSOCIATED INFECTIONS

(57) Abstract: Provided herein are methods for treating or preventing inflammation, inflammatory conditions and autoimmune conditions, optionally of the gastrointestinal tract, urinary tract, skin, nails or joints. Also provided are methods of treating or preventing bacterial infections, typically infections associated with inflammation, inflammatory conditions and autoimmune conditions of the gastrointestinal tract, urinary tract, skin, nails or joints. The methods of the present disclosure comprise administering to a subject in need a *Lactobacillus* species selected from *Lactobacillus buchneri*, *Lactobacillus zeae*, *Lactobacillus rami*, *Lactobacillus paracasei*, *Lactobacillus parafarraginis*, and *Lactobacillus diolivorans*, and/or a culture supernatant or cell free filtrate derived from culture media in which the *Lactobacillus* has been cultured.



WO 2020/073088 A1